CoverageForm 410-K10-Q8-K13D13G13F

MNKD · Mannkind Corp - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Price · MNKD

Income Statement

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Revenue$90.17M-$82.13M$76.53M$78.35M-$70.08M$72.39M$66.26M-
Cost of Revenue$7.51M-$4.50M$4.61M$3.77M-$3.20M$5.61M$3.82M-
Gross Profit$82.66M-$77.63M$71.92M$74.59M-$66.88M$66.78M$62.44M-
R&D$17.23M-$14.06M$13.68M$11.02M-$12.93M$11.82M$10.01M-
SG&A$54.09M-$29.09M$24.11M$22.33M-$10.82M$12.62M$10.73M-
Total Operating Expenses$91.84M-$63.23M$71.23M$56.06M-$18.02M$20.38M$18.60M-
D&A$6.38M-$2.01M$2.04M$2.11M-$2.10M$1.71M$1.36M-
Operating Income($1.67M)-$18.90M$5.30M$22.29M-$12.76M$16.61M$16.72M-
Interest Expense$7.48M-$1.36M$6.05M$2.57M-$2.81M$6.05M$2.57M-
Income Tax$253.0K-($204.0K)$272.0K$459.0K-$1.32M$323.0K$264.0K-
Net Income($16.62M)-$7.99M$668.0K$13.16M-$11.55M($2.01M)$10.63M-
EPS - Basic($0.05)-$0.03$0.00$0.04-$0.04($0.01)$0.04-
EPS - Diluted($0.05)-$0.03$0.00$0.04-$0.04($0.01)$0.04-

Balance Sheet

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Cash & Equivalents$52.83M$74.88M$127.39M$57.01M$47.31M$46.34M$62.37M$96.64M$193.27M$238.48M
Accounts Receivable$28.14M$38.37M$17.38M$27.14M$28.90M$11.80M$18.18M$23.35M$19.91M$14.90M
Inventory$49.17M$35.31M$26.97M$28.49M$28.89M$27.89M$26.66M$24.75M$26.44M$28.55M
Accounts Payable$16.14M$9.03M$7.27M$10.26M$5.04M$6.79M$6.44M$9.56M$7.15M$9.58M
Current Assets$251.16M$291.58M$358.84M$279.03M$273.74M$268.31M$327.66M$325.94M$383.10M$373.39M
Total Assets$744.40M$792.18M$494.64M$411.70M$410.14M$393.84M$464.20M$443.84M$480.88M$475.20M
Current Liabilities$134.56M$171.03M$109.13M$111.83M$115.94M$81.84M$72.10M$80.01M$99.90M$104.13M
Long-term Debt$318.72M$354.64M$109.65M$36.17M$36.11M$36.05M$227.94M$227.58M$264.15M$268.70M
Total Liabilities$803.60M$843.20M$539.19M$466.74M$468.76M$472.66M$674.13M$669.62M$710.85M$721.37M
Stockholders' Equity($59.20M)($51.02M)($44.55M)($55.04M)($58.62M)($78.82M)($209.93M)($225.78M)($229.97M)($246.17M)
Retained Earnings($3.21B)($3.20B)($3.18B)($3.19B)($3.19B)($3.20B)($3.21B)($3.22B)($3.22B)($3.23B)

Cash Flow

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Operating Cash Flow($5.37M)---($6.38M)---$6.70M-
Investing Cash Flow$18.73M---$5.96M---($48.44M)-
Financing Cash Flow($35.41M)---$1.39M---($3.47M)-
CapEx$1.88M---$330.0K---$2.41M-
Free Cash Flow($7.25M)---($6.71M)---$4.29M-

Ratios

MetricQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Profitability
Gross margin91.7%-94.5%94.0%95.2%-95.4%92.3%94.2%-
Operating margin-1.8%-23.0%6.9%28.5%-18.2%22.9%25.2%-
EBITDA margin5.2%-25.5%9.6%31.1%-21.2%25.3%27.3%-
Net margin-18.4%-9.7%0.9%16.8%-16.5%-2.8%16.0%-
Free cash flow margin-8.0%----8.6%---6.5%-
FCF / Net income0.44----0.51---0.40-
R&D / Revenue19.1%-17.1%17.9%14.1%-18.4%16.3%15.1%-
SG&A / Revenue60.0%-35.4%31.5%28.5%-15.4%17.4%16.2%-
Effective tax rate---2.6%28.9%3.4%-10.3%-2.4%-
Return on assets-2.2%-1.6%0.2%3.2%-2.5%-0.5%2.2%-
Return on equity28.1%--17.9%-1.2%-22.4%--5.5%0.9%-4.6%-
Return on invested capital-0.5%-29.0%---63.6%730.2%47.7%-
Liquidity
Current ratio1.871.703.292.502.363.284.544.073.843.59
Quick ratio1.501.503.042.242.112.944.173.763.573.31
Cash ratio0.390.441.170.510.410.570.871.211.932.29
Leverage
Debt / Equity-5.38-6.95-2.46-0.66-0.62-0.46-1.09-1.01-1.15-1.09
Debt / Assets0.430.450.220.090.090.090.490.510.550.57
Debt / EBITDA67.60-5.244.931.48-15.3412.4214.61-
Interest coverage-0.2x-13.9x0.9x8.7x-4.5x2.7x6.5x-
Equity multiplier-12.58-15.53-11.10-7.48-7.00-5.00-2.21-1.97-2.09-1.93
Liabilities / Assets1.081.061.091.131.141.201.451.511.481.52
Efficiency
Asset turnover0.12-0.170.190.19-0.150.160.14-
Inventory turnover0.15-0.170.160.13-0.120.230.14-
Days sales outstanding114d-77d129d135d-95d118d110d-
Days inventory outstanding2390d-2189d2257d2799d-3044d1612d2527d-
Days payable outstanding785d-590d813d488d-736d622d683d-
Cash conversion cycle1719d-1676d1574d2445d-2403d1107d1954d-
Valuation
P / E--179.0x-125.8x-157.3x-113.3x-
P / B----------
P / S8.4x-20.4x15.2x20.6x-25.6x19.7x22.2x-
EV / EBITDA216.6x-79.2x155.9x65.7x-131.7x84.9x85.3x-
Growth
Revenue growth (YoY)15.1%-17.2%5.7%18.2%-36.7%48.9%63.1%-
Revenue CAGR (3y)30.4%-35.8%59.4%86.9%-46.7%46.0%56.1%-
Revenue CAGR (5y)38.9%-39.9%38.3%37.0%-36.9%37.0%30.6%-
Gross profit growth (YoY)10.8%-16.1%7.7%19.4%-41.5%53.9%77.9%-
Operating income growth (YoY)--48.1%-68.1%33.3%-150.3%865.1%--
Net income growth (YoY)---30.9%-23.8%-571.1%61.7%--
EPS growth (YoY)---25.0%-0.0%-300.0%50.0%--
EPS CAGR (3y)----------
EPS CAGR (5y)----------
FCF growth (YoY)-8.0%---------
FCF CAGR (5y)----------
Book value growth (YoY)-1.0%35.3%78.8%75.6%74.5%68.0%16.6%13.3%10.0%1.7%

Sales by segment

From XBRL dimensional facts in the 10-K period ending 2025-12-31.

Business segments

$348.97M total
All Other Segments$348.97M · 100.0%

Product / service

$685.55M total
Product Revenue$216.52M · 31.6%
Royalty$128.12M · 18.7%
Product$114.14M · 16.6%
License And Service$106.71M · 15.6%
Afrezza$74.59M · 10.9%
Furoscix$23.18M · 3.4%
VGo$16.37M · 2.4%
Service$4.33M · 0.6%
Manufacturing Services$1.60M · 0.2%

Peer comparison

Same SIC group: Pharmaceutical Preparations

CompanyRevenue (last FY)Net marginROE
LLY$65.18B31.7%77.8%
UTHR$3.18B41.9%18.8%
PFE$62.58B12.4%9.0%
ZTS$9.47B28.2%80.2%
VRTX$12.00B32.9%21.2%

Comparing MANNKIND CORP against the 5 most active filers in the same SIC group.